Prof Sanjay Popat speaks to ecancer about the challenges in first line ALK positive NSCLC management and the emerging data on ALK TKIs in ALK positive NSCLC from ESMO and WCLC 2021.
Initially, he shares his expert opinion on the latest data and discussions from WCLC and ESMO 2021 regarding ALK positive NSCLC. Prof Popat then discusses the challenges associated with 1L ALK positive NSCLC management. He talks about the ALTA-1L final analysis, phase III CROWN study and BrigALK2 study.
Prof Popat also mentions the unique efficacy of ensartinib on different ALK fusion subtypes evaluated by plasma ctDNA. He concludes by talking about what the future looks like for the treatment of ALK positive NSCLC.
|Efficacy of Ensartinib on Different ALK Fusion Subtypes Evaluated by Plasma ctDNA|
|Challenges regarding 1L ALK+ NSCLC management|
|Future treatment of ALK+ NSCLC|
ecancer's filming has been kindly supported by Takeda through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.